Aktuellt
SENASTE
Redeye provides an update in relation to Enzymatica’s Q2 2023 report. The report did not include any major surprises, in our view, and was fairly in line with our expectations. We have chosen to only make some minor estimate changes for Q3-Q4 2023 and believe the company has an important half-year ahead with positive study results and rising sales as potential triggers for the share. The estimate changes we have made do not render any changes in our fair value range, including a base case of SEK6.5.
LÄS MER
